Expert Interview
Examining Argenx' Phase 2 studies evaluating VYVGART (IV: efgartigimod alfa-fcab) in Sjogren’s disease (SjD) and idiopathic inflammatory myopathies (IIM or myositis) presented at EULAR 2025
Ticker(s): ARGXInstitution: University of Pittsburgh Medical Center
- Assistant Professor of Medicine and Staff Rheumatologist-University of Pittsburgh Medical Center.
- Manages 80 patients/yr with Myositis; 50 patients/yr with Sjogren's Disease,180 patients with rheumatoid arthritis, and 50 patients with Systemic Lupus Erythematosus.
- Research interests include inflammatory myopathies and biomarker clinical studies.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
